Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers

Porter, R; McAllister-Williams, R. Hamish; Young, A. W.

doi:10.1007/s002130051106

Cited by 16 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In healthy subjects, acute administration of the TCA, clomipramine, increases the GH response to L-tryptophan [Anderson and Cowen, 1986]. Likewise, administration of 18.75 mg of venlafaxine to 12 healthy male volunteers 3 hr before infusion of L-tryptophan significantly enhanced the GH response compared to pretreatment with placebo [Porter et al, 1999]. These results are consistent with venlafaxine acting to enhance serotonergic neurotransmission through 5HT 1A postsynaptic receptors.…”

Section: Neuroendocrinesupporting

confidence: 77%

Neuropharmacology of venlafaxine

Roseboom¹,

Kalin²

2000

Depress. Anxiety

View full text Add to dashboard Cite

Section: Neuroendocrinesupporting

confidence: 77%

Neuropharmacology of venlafaxine

Roseboom¹,

Kalin²

2000

Depress. Anxiety

View full text Add to dashboard Cite

“…Preclinical studies have revealed that venlafaxine is equipotent to paroxetine with regard to the inhibition of the firing of the serotonin neurons in the dorsal raphe. 27 The similar clinical efficacy of venlafaxine and paroxetine in OCD might therefore be explained by an equivalent activity on the serotonergic system. In addition, at higher doses, venlafaxine also blocks the uptake of norepinephrine.…”

Section: Discussionmentioning

confidence: 98%

A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder

Denys

Wee

Megen

et al. 2003

Journal of Clinical Psychopharmacology

119

View full text Add to dashboard Cite

While the usefulness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in obsessive-compulsive disorder (OCD) has been established, the efficacy of serotonin-norepinephrine reuptake inhibitors remains to be determined. This report describes the first randomized double-blind comparison study of an SNRI in patients with obsessive-compulsive disorder. The current study compares the efficacy and tolerability of venlafaxine with paroxetine. One hundred and fifty patients with primary OCD according to DSM-IV criteria were randomly assigned in a 12-week double-blind trial to receive dosages titrated upward to 300 mg/d of venlafaxine (n = 75) or 60 mg/d of paroxetine (n = 75). Primary efficacy was assessed by the change from baseline on the Yale-Brown obsessive-compulsive scale (Y-BOCS). Other assessments throughout the trial included the Hamilton depression rating scale, and the Hamilton anxiety rating scale. An intent-to-treat, last-observation-carried-forward analysis demonstrated a mean decrease on the Y-BOCS of 7.2 +/- 7.5 in the venlafaxine group and of 7.8 +/- 5.4 in the paroxetine group. In both treatment groups, a responder rate (decrease > 35% on the Y-BOCS) of approximately 40% was found. There were no significant differences between venlafaxine and paroxetine with regard to response or responder rates. The incidence of adverse events for venlafaxine and paroxetine was comparable. The most common side effects for venlafaxine were somnolence, insomnia, a dry mouth, and sweating; and for paroxetine somnolence, sweating, nausea, and headache. These results show that venlafaxine was equally effective to paroxetine in treating patients with OCD. Venlafaxine may be a useful therapy for obsessive-compulsive patients, but is not superior to SSRIs.

show abstract

“…These doses were selected to minimize the risk of adverse side effects reported in the literature with higher doses of these medications. Although the serotonergic effects of venlafaxine-XR predominate at lower doses of the medication, we would expect some noradrenergic activity at the dose (75 mg daily) used in this study (23).…”

Section: Study Medicationsmentioning

confidence: 89%

“…Venlafaxine is an antidepressant that inhibits the reuptake of both serotonin and (at higher doses) norepinephrine (23). Adverse event reports suggest it may have gastrointestinal effects, because nausea and vomiting occur in 10-43 and 6-10% of patients, respectively (21).…”

mentioning

confidence: 99%

Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health

Chial

Camilleri

Burton

et al. 2003

American Journal of Physiology-Gastrointestinal and Liver Physi

112

View full text Add to dashboard Cite

This study evaluated the effects of serotonergic psychoactive agents on gastrointestinal functions in healthy human subjects. Participants received one of four regimens in a randomized, double-blind manner: buspirone, a 5-HT1Areceptor agonist (10 mg twice daily); paroxetine, a selective serotonin reuptake inhibitor (20 mg daily); venlafaxine-XR, a selective serotonin and norepinephrine reuptake inhibitor (75 mg daily); or placebo for 11 days. Physiological testing performed on days 8–11included scintigraphic assessment of gastrointestinal and colonic transit, the nutrient drink test, and assessment of the postprandial change in gastric volume. Fifty-one healthy adults (40 females, 11 males) participated in this study. No effects on gastric emptying or colonic transit were identified with any agent. Small bowel transit of a solid meal was accelerated by paroxetine. Buspirone decreased postprandial aggregate symptom and nausea scores. Venlafaxine-XR increased the postprandial change in gastric volume. Buspirone, paroxetine, and venlafaxine-XR affect upper gastrointestinal functions in healthy humans. These data support the need for clinical and physiological studies of these agents in functional gastrointestinal disorders.

show abstract

Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers

Abstract: The data suggest enhancement of transmission through postsynaptic 5-HT(1A) receptors by venlafaxine but not paroxetine, after only 3 h.

Cited by 16 publications

References 30 publications

Neuropharmacology of venlafaxine

Neuropharmacology of venlafaxine

A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder

Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health

Contact Info

Product

Resources

About